Pradaxa prescribed | dabigatran etexilate | Vitamin K antagonists | Stroke prevention | Atrial Fibrillation | Heart Valve Involvement Absent
Item
newly prescribed treatment with pradaxa® (dabigatranetexilat)/vitamine k antagonist (vka) in indication stroke prevention in non-valvular atrial fibrillation (af), respecting indication and contraindications as described in the respective summary of product characteristics for pradaxa®110 mg resp. 150 mg capsules, resp. vka.
boolean
C2940579 (UMLS CUI [1,1])
C0278329 (UMLS CUI [1,2])
C1571583 (UMLS CUI [2])
C3653316 (UMLS CUI [3])
C1277289 (UMLS CUI [4])
C0004238 (UMLS CUI [5])
C0018826 (UMLS CUI [6,1])
C1314939 (UMLS CUI [6,2])
C0332197 (UMLS CUI [6,3])
Patients Appropriate Pradaxa | Patients Appropriate Vitamin K antagonists
Item
patients suitable for therapy with pradaxa as well as with vka.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C2940579 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C3653316 (UMLS CUI [2,3])
dabigatran etexilate | Vitamin K antagonists
Item
treatment with dabigatranetexilat resp. vka follows summary of product characteristics.
boolean
C1571583 (UMLS CUI [1])
C3653316 (UMLS CUI [2])
Routine Diagnostic unchanged | Routine Treatment unchanged
Item
the usual routine in diagnostics and treatment will not be modified.
boolean
C0205547 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C0442739 (UMLS CUI [1,3])
C0205547 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0442739 (UMLS CUI [2,3])
Qualification Vitamin K antagonists | Qualification Dabigatran etexilate
Item
only patients will be documented qualifying for vka-therapy as well as for dabigatranetexilat acc. to pradaxa® resp. vka summary of product characteristics.
boolean
C1709790 (UMLS CUI [1,1])
C3653316 (UMLS CUI [1,2])
C1709790 (UMLS CUI [2,1])
C1571583 (UMLS CUI [2,2])
Informed Consent
Item
written informed consent before inclusion.
boolean
C0021430 (UMLS CUI [1])
Medical contraindication General | Medical contraindication Special
Item
patients with general or special contraindications acc. to summary of product characteristics.
boolean
C1301624 (UMLS CUI [1,1])
C0205246 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0205555 (UMLS CUI [2,2])
Study Subject Participation Status | Clinical Trial Without Interventional procedure | Interventional Study
Item
patients participating at the same time or within the last 30 days in another non-interventional study (nis) or interventional clinical trial.
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C0332288 (UMLS CUI [2,2])
C0184661 (UMLS CUI [2,3])
C3274035 (UMLS CUI [3])
Patient need for Anticoagulation Therapy | Exception Indication Atrial Fibrillation
Item
patients needing anticoagulative treatment for indications other than non-valvular atrial fibrillation.
boolean
C0686904 (UMLS CUI [1,1])
C0003281 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C3146298 (UMLS CUI [2,2])
C0004238 (UMLS CUI [2,3])
Pregnancy | Breast Feeding
Item
pregnancy or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])